Articles from HMNC Holding GmbH

HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder

Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder

By HMNC Holding GmbH · Via GlobeNewswire · July 22, 2025

HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder

Study Marks Milestone in Precision Psychiatry for Stress-Axis-Related Depression

By HMNC Holding GmbH · Via GlobeNewswire · January 10, 2025

HMNC Brain Health Collaborates with the Austrian Institute of Technology and the Danube Private University to Win Grant from the Austrian Research Promotion Agency

Grant for "Personalized Medicine Enabled by Intelligent Sensing Systems” Project

By HMNC Holding GmbH · Via GlobeNewswire · December 11, 2024

HMNC Brain Health to Present Advances in Precision Psychiatry and Psychedelics at CNS Summit 2024 in Boston

Company Leaders To Contribute to Key Discussions On The Future Of Mental Health Treatment, Unveiling Innovations In Genetic Companion Diagnostics And Psychedelic Therapies

By HMNC Holding GmbH · Via GlobeNewswire · October 31, 2024